Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery

References

• Gribble GW. Naturally occurring organofluorines. The Handbook of Environmental Chemistry, (Springer-verlag). 2002;3:121–136.
   Google Scholar
• Fried J, Sabo EF. Synthesis of 17α-Hydroxycorticostereone and its 9α-Halo Derfivatives from 11-Epi-17α-Hydroxycorticostereone. J Am Chem Soc. 1953;75:2273–2274.
   Web of Science ®Google Scholar
• Fried J, Sabo EF. 9α-fluoro derivatives of cortisone and hydrocortisone. J Am Chem Soc. 1954;76:1455–1456.
   Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Gillis EP, Eastman KJ, Hill MD, et al. Applications of fluorine in medicinal chemistry. J Med Chem. 2015 Jul 22;58:8315–8359.
   PubMed Web of Science ®Google Scholar
• Purser S, Moore PR, Swallow S, et al. Fluorine in medicinal chemistry. Chem Soc Rev. 2008;37:320–330.
   PubMed Web of Science ®Google Scholar
• Hagmann WK. The many roles for fluorine in medicinal chemistry. J Med Chem. 2008;51:4359–4369.
   PubMed Web of Science ®Google Scholar
• Kirk KL. Selective fluorination in drug design and development: an overview of biochemical rationales. Curr Top Med Chem. 2006;6:1447–1456.
   PubMed Web of Science ®Google Scholar
• Sun S, Adejare A. Fluorinated molecules as drugs and imaging agents in the CNS. Curr Top Med Chem. 2006;6:1457–1464.
   PubMed Web of Science ®Google Scholar
• O’Hagan D. Understanding organofluorine chemistry. An introduction to the C-F bond. Chem Soc Rev. 2008;37:308–319.
   PubMed Web of Science ®Google Scholar
• Upadhyay C, Chaudhary M, De Oliveira RN, et al. Fluorinated scaffolds for antimalarial drug discovery. Expert Opin Drug Disc. 2020 Mar 21;15(6):705–718. .
   PubMed Web of Science ®Google Scholar
• Bohm HJ, Banner D, Bendels S, et al. Fluorine in medicinal chemistry. ChemBioChem. 2004;5:637–643. .
   PubMed Web of Science ®Google Scholar
• Müller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science. 2007;317:1881–1886.
   PubMed Web of Science ®Google Scholar
• Filler R, Saha R. Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. Future Med Chem. 2009;1:777–791. .
   PubMed Web of Science ®Google Scholar
• Meanwell NA. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. J Med Chem. 2018 Feb 5;61:5822–5880. .
   PubMed Web of Science ®Google Scholar
• Smart BE. Fluorine substituent effects (on bioactivity). J Fluorine Chem. 2001;109:3–11.
   Web of Science ®Google Scholar
• Bondi A. Van der waals volumes and radii. J Phys Chem. 1964;68:441–451.
   Web of Science ®Google Scholar
• Schlosser M, Michel M. About the “physiological size” of fluorine substituents: comparison of sensorially active compounds with fluorine and methyl substituted analogues. Tetrahedron. 1996;52:99–108.
   Web of Science ®Google Scholar
• Landry ML, Crawford JJ. LogD contributions of substituents commonly used in medicinal chemistry. ACS Med Chem Lett. 2020 Dec 11;11:72–76. .
   PubMed Web of Science ®Google Scholar
• Morgenthaler M, Schweizer E, Hoffmann-Röder A, et al. Predicting properties and tuning physicochemical in lead optimization: amine basicities. ChemBioChem. 2007;2:1100–1115.
   Google Scholar
• Rodrigues Silva D, Daré J, Freitas MP. Conformational preferences of fluorine-containing agrochemicals and their implications for lipophilicity prediction. Beilstein J Org Chem. 2020 Oct 5;16:2469–2476. .
   PubMed Web of Science ®Google Scholar
• Dunitz JD. Organic fluorine: odd man out. ChemBioChem. 2004;5:614–621.
   PubMed Web of Science ®Google Scholar
• Fischer F, Schweizer WB, Diederich F. Molecular torsion balances: evidence for favorable orthogonal dipolar interactions between organic fluorine and amide groups. Angew Chem Int Ed. 2007;46:8270–8273.
   PubMed Web of Science ®Google Scholar
• Paulini R, Müller K, Diederich F. Orthogonal multipolar interactions in structural chemistry and biology. Angew Chem Int Ed. 2005;44:1788–1805.
   PubMed Web of Science ®Google Scholar
• DiMagno SG, Sun H. The strength of weak interactions: aromatic fluorine in drug design. Curr Top Med Chem. 2006;6:1473–1482.
   PubMed Web of Science ®Google Scholar
• Mehta G, Sen S. Probing fluorine interactions in a polyhydroxylated environment: conservation of a C–F···H–C recognition motif in presence of O–H···O hydrogen bonds. Eur J Org Chem. 2010;2010:3387–3394.
   Web of Science ®Google Scholar
• Richardson P. Fluorination methods for drug discovery and development. Exp Opin Drug Disc. 2016 Aug 30;11(10):983–999.
   PubMed Web of Science ®Google Scholar
• Murphy CD, Sanford G. Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity. Exp Opin Drug Metabol Tox. 2015 Mar 2;11(4):589–599. .
   PubMed Web of Science ®Google Scholar
• Champagne PA, Desroches J, Hamel JD, et al. Monofluorination of Organic Compounds: 10 Years of Innovation. Chem Rev. 2015;115:9073–9174.
   PubMed Web of Science ®Google Scholar
• Campbell M, Ritter T. Modern carbon-fluorine bond forming reactions for aryl-fluoride synthesis. Chem Rev. 2015;115:612–633.
   PubMed Web of Science ®Google Scholar
• Liang T, Neumann C, Ritter T. Introduction of Fluorine and Fluorine-Containing Functional Groups. Angew Chem Int Ed. 2013;52:8214–8264.
   PubMed Web of Science ®Google Scholar
• Furuya T, Kuttruff CA, Ritter T. Carbon-fluorine bond formation. Curr Opin Drug Disc. 2008;11:803–819.
   PubMedGoogle Scholar
• Kirk KL. Fluorination in medicinal chemistry: methods, strategies, and recent developments. Org Process Res Dev. 2008;12:305–321.
   Web of Science ®Google Scholar
• Kirsch P. Modern fluoroorganic chemistry: synthesis, reactivity, applications. Weinheim, Germany: Wiley-VCH; 2004.
   Google Scholar
• Furuya T, Klein JEMN, Ritter T. C-F bond formation for the synthesis of aryl fluorides. Synthesis. 2010;42:1804–1821.
   Google Scholar
• Shimizu M, Hiyama T. Modern synthetic methods for fluorine-substituted target molecules. Angew Chem Int Ed. 2005;44:214–231.
   Web of Science ®Google Scholar
• Gerstenberger MRC, Haas A. Methods of fluorination in organic chemistry. Angew Chem Int Ed. 1981;20:647–667.
   Web of Science ®Google Scholar
• Wang J, Sánchez-Roselló M, Aceňa JL, et al. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Chem Rev. 2014;114:2432–2506.
   PubMed Web of Science ®Google Scholar
• Harsanyi A, Sandford G. Organofluorine chemistry: applications, sources and sustainability. Green Chem. 2015;17:2081–2086. .
   Web of Science ®Google Scholar
• Moir M, Danon JJ, Reekie TA, et al. An overview of late-stage functionalization in today’s drug discovery. Exp Opin Drug Disc. 2019 Aug 14;14(11):1137–1149. .
   PubMed Web of Science ®Google Scholar
• Sladojevich F, Arlow S, Tang P, et al. Late-stage deoxyfluorination of alcohols with phenofluor. J Am Chem Soc. 2013;135:2470–2473.
   PubMed Web of Science ®Google Scholar
• Campbell M, Ritter T. Late-stage fluorination: from fundamentals to application. Org Process Res Dev. 2014;18:474–480.
   PubMed Web of Science ®Google Scholar
• Neumann CN, Ritter T. Late-stage fluorination: fancy novelty or useful tool? Angew Chem Int Ed. 2015;54:3216–3221.
   PubMed Web of Science ®Google Scholar
• Postigo A. Late stage fluorination of bioactive molecules and biologically relevant substrates. Amsterdam, Netherlands: Elsevier; 2018.
   Google Scholar
• Szpera R, Moseley DFJ, Smith LB, et al. The fluorination of C-H bonds: developments and perspectives. Angew Chem Int Ed. 2019;58:14824–14848. .
   PubMed Web of Science ®Google Scholar
• Inoue M, Sumii Y, Shibata N. Contribution of organofluorine compounds to pharmaceuticals. ACS Omega. 2020 Apr 22;5:10633–10640. .
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang J, Gu Z, et al. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas. Chem Rev. 2016;116:7193–7214.
   Web of Science ®Google Scholar
• New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. FDA. Washington DC: FDA Center for drug evaluation and research, 2020. [cited 2021 Jan 18th]. Available at www.fed.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.
   Google Scholar
• Meanwell NA. Synopsis of some recent tactical applicatons of bioisosteres in drug design. J Med Chem. 2011 Mar 17;54:2529–2591.
   PubMed Web of Science ®Google Scholar
• Meanwell NA. The influence of bioisosteres in drug design: tactical applications to address developability problems. Top Med Chem. 2015;9:238–382.
   Google Scholar
• Patani GA, LaVoie EJ. Bioisoserism: a rational approach in drug design. Chem Rev. 1996;96:3147–3176.
   PubMed Web of Science ®Google Scholar
• Brown N. Bioisosteres in medicinal chemistry. Weinheim: Wiley-VCH Verlag; 2012.
   Google Scholar
• Lipinski CA. Bioisosterism in drug design. Annu Rep Med Chem. 1986;21:283–291.
   Google Scholar
• Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem. 2005;12:23–49.
   PubMed Web of Science ®Google Scholar
• Olesen PH. The use of bioisosteric groups in lead optimization. Curr Opin Drug Discovery Dev. 2001;4:471–478.
   PubMedGoogle Scholar
• Lie JJ. Medicinal chemistry for practitioners. Ch 4. Bioisosteres. 2020:225-306. (Wiley).
   Google Scholar
• Lima LM, Barreiro EJ. Beyond bioisosterism: new concepts in drug discovery. Compr Med Chem III. 2017;1: 186–210. (Elsevier).
   Google Scholar
• Langdon SR, Ertl P, Brown N. Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol Inf. 2010;29:366–385.
   PubMed Web of Science ®Google Scholar
• Langmuir I. Isomorphism, isosterism and covalence. J Am Chem Soc. 1919;41:1543–1559.
   Google Scholar
• Grimm HG. Structure and size of the non-metallic hydrides. Zeitsc Elektrochem. 1925;31:474–480.
   Google Scholar
• Grimm HG. The system of chemical compounds from the viewpoint of atom research, several problems of experimental research. Part I Naturwissenschaften. 1929;17:535–540.
   Google Scholar
• Grimm HG. The system of chemical compounds from the viewpoint of atom research, several problems of experimental research. Part II Naturwissenschaften. 1929;17:557–564.
   Google Scholar
• Erlenmeyer H, Leo M. Über Pseudoatome. Helv Chim Acta. 1932;15:1171–1186.
   Google Scholar
• Erlenmeyer H, Berger E. Studies on the significance of structure of antigens for the production and the specificity of antibodies. Biochem Z. 1932;252:22–36.
   Google Scholar
• Erlenmeyer H, Berger E, Leo M. Relationship between the structure of antigens and the specificity of antibodies. Helv Chim Acta. 1933;16:733–738.
   Google Scholar
• Erlenmeyer H. Les composes isostères et le problème de la resemblance en chimie. Bull Soc Chim Biol. 1948;30:792–805.
   Google Scholar
• Friedman HL. Influence of isosteric replacements on biological activity. Symposium on chemical-biological correlation. Natl Res Council Publ. 1951;206: 295–362. (Washington DC).
   Google Scholar
• Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev. 1979;8:563–580.
   Web of Science ®Google Scholar
• Burger A. Isosterism and bioisosterism in drug design. Progress Drug Res. 1991;37:288–362.
   Google Scholar
• Martin YC. A practitioner’s perspective of the role of quantitative structure-activity analysis in medicinal chemistry. J Med Chem. 1981;24:229–237.
   PubMed Web of Science ®Google Scholar
• Papadatos G, Brown N. In silico applications of bioisosterism in contemporary medicinal chemistry. J Chem Info Model. 2013;3:339–354.
   Google Scholar
• Chenoweth MB, McCarthy LB. On the mechanism of the pharmacophoric effect of halogenation. Pharmacol Rev. 1063;15:673–707.
   Google Scholar
• Goldman P. The carbon-fluorine bond in compounds of biological interest. Science. 1969;164:1123–1130.
   PubMed Web of Science ®Google Scholar
• Shanu-Wilson J, Evans L, Wrigley S, et al. Biotransformation: impact and application of metabolism in drug discovery. ACS Med Chem Lett. 2020 Aug 28;11:2087–2107.
   PubMed Web of Science ®Google Scholar
• Xing L, Keefer C, Brown MF. Fluorine multipolar interaction: toward elucidating its energetics in binding recognition. J Fluorine Chem. 2017 Dec 3;198:47–53.
   Web of Science ®Google Scholar
• Obst U, Gramlich V, Diederich F, et al. Design of novel, nonpeptidic thrombin inhibitors and structure of a thrombin–inhibitor complex. Angew Chem Int Ed. 1995 Sept 1;34:1739–1742.
   Web of Science ®Google Scholar
• Obst U, Banner DW, Weber F, et al. Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. Chem Biol. 1997 Apr 4;4:287–295.
   PubMedGoogle Scholar
• Schärer K, Morgenthaler M, Seiler P, et al. Enantiomerically pure thrombin inhibitors for exploring the molecular‐recognition features of the oxyanion hole. Helv Chim Acta. 2004 Oct 21;87:2517–2538.
   Web of Science ®Google Scholar
• Obst U, Betschmann P, Lerner C, et al. Synthesis of novel nonpeptidic thrombin inhibitors. Helv Chim Acta. 2000 May 4;83:855–909.
   Web of Science ®Google Scholar
• Betschmann P, Sahli S, Diederich F, et al. Structure‐based design of nonpeptidic thrombin inhibitors: exploring the D‐pocket and the oxyanion hole. Helv Chim Acta. 2002 May 29;85:1210–1245.
   Web of Science ®Google Scholar
• Olsen JA, Banner DW, Seiler P, et al. A Fluorine Scan of Thrombin Inhibitors to Map the Fluorophilicity/Fluorophobicity of an Enzyme Active Site: evidence for C-F⋅⋅⋅C-O Interactions. Angew Chem Int Ed. 2003 Jun 5;42:2507–2511.
   PubMed Web of Science ®Google Scholar
• Olsen JA, Banner DW, Seiler P, et al. Fluorine interactions at the thrombin active site: protein backbone fragments H-Cα-C-O comprise a favorable C-F environment and interactions of C-F with electrophiles. ChemBioChem. 2004 Apr 28;5:666–675.
   PubMed Web of Science ®Google Scholar
• Paulini R, Müller K, Diederich F. Orthogonal multipolar interactions in structural chemistry and biology. Angew Chem Int Ed. 2005 Mar 8;44:1788–1805.
   PubMed Web of Science ®Google Scholar
• Hof F, Scotfield DM, Schweizer WB, et al. A weak attractive interaction between organic fluorine and an amide group. Angew Chem Int Ed. 2004 Sept 22;43:5056–5059.
   PubMed Web of Science ®Google Scholar
• Olsen J, Seiler P, Wagner B, et al. A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C–F⋯CN interactions. Org Biomol Chem. 2004 Apr 14;2:1339–1352.
   PubMed Web of Science ®Google Scholar
• Schweizer E, Hoffmann-Röder A, Diederich F, et al. A fluorine scan at the catalytic center of thrombin: c-F, C-OH and C-OMe Bioisosterism and Fluorine Effects on pKa and logD Values. Chem Med Chem. 2006 Apr 20;1:611–621. .
   Google Scholar
• Earl J, Kirkpatrick P. Fresh from the pipeline: ezetimibe. Nat Rev Drug Discovery. 2003;2(2):97–98.
   PubMedGoogle Scholar
• Darkes MJM, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs. 2003;3(1):67–76.
   PubMedGoogle Scholar
• Bruckert E. New lipid-modifying therapies. Expert Opin Invest Drugs. 2003;12(3):325–335.
   PubMed Web of Science ®Google Scholar
• Gylling H, Miettinen TA. Combination therapy with statins. Curr Opin Invest Drugs. 2002;3(9):1318–1323.
   PubMedGoogle Scholar
• Gupta EK, Ito MK. Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart Dis. 2002;4(6):399–409.
   PubMedGoogle Scholar
• Bays H. Ezetimibe. Expert Opin Invest Drugs. 2002;11(11):1587–1604.
   PubMed Web of Science ®Google Scholar
• Meng CQ. Ezetimibe schering plough. Curr Opin Invest Drugs. 2002;3(3):427–432.
   PubMedGoogle Scholar
• Sliskovic DR, Picard JA, Krause BR. ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem. 2002;3:121–171.
   Google Scholar
• Clader JW, Berger JG, Burrier RE, et al. Substituted (1,2-diarylethyl)amide acyl CoA: cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J Med Chem. 1995;38:1600–1607.
   PubMed Web of Science ®Google Scholar
• Vaccaro W, Amore C, Berger J, et al. Inhibitors of Acyl CoA: cholesterol Acyltransferase. J Med Chem. 1996;39:1704–1719.
   PubMed Web of Science ®Google Scholar
• Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-artherosclerotic agents. Trends Pharmacol Sci. 1991;323:1289–1298.
   Google Scholar
• Burnett DA, Caplen MA, Davies HR, et al. 2-azetidinones as inhibitors of cholesterol absorption. J Med Chem. 1994;37:1733–1736.
   PubMed Web of Science ®Google Scholar
• Clader JW, Burnett DA, Caplen MA, et al. 2-azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus. J Med Chem. 1996;39:3684–3693.
   PubMed Web of Science ®Google Scholar
• Burnett DA. β-lactam cholesterol absorption inhibitors. Curr Med Chem. 2004;11(14):1873–1888.
   PubMed Web of Science ®Google Scholar
• Clader JW. Ezetimibe and other azetidinone cholesterol absorption inhibitors. Curr Top Med Chem. 2005;5(3):243–256.
   PubMed Web of Science ®Google Scholar
• Dugar S, Clader JW, Chan T-M, et al. Substituted 2-azaspiro[5.3]nonan-1-ones as potent chlolesterol absorption inhibitors. defining a binding conformation of SCH 46461. J Med Chem. 1995;38:4875–4877.
   PubMed Web of Science ®Google Scholar
• Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through identification of the active metabolites of SCH 48461. J Pharmacol Exp Ther. 1997;283:157–163.
   PubMed Web of Science ®Google Scholar
• McKittrick BA, Na K, Dugar S, et al. Stereoselective synthesis and biological activity of cis-azetidinones as cholesterol absorption inhibitors. Bioorg Med Chem Lett. 1996 Aug 20;6:1947–1950.
   Web of Science ®Google Scholar
• Dugar S, Yumibe N, Clader JW, et al. Metabolism and structure-activity data-based design. Discovery of (-) SCH 53079. An analog of the potent cholesterol absorption inhibitor (-) SCH 48461. Bioorg Med Chem Lett. 1996;6:1271–1274.
   Web of Science ®Google Scholar
• Kirkup MP, Rizvi R, Shankar B, et al. (-) SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor. Bioorg Med Chem Lett. 1996;6:2069–2072.
   Web of Science ®Google Scholar
• McKittrick BA, Ma K, Huie K, et al. Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity. J Med Chem. 1998;41:752–759.
   PubMed Web of Science ®Google Scholar
• Rosenblum SB, Huynh T, Afonso A, et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally available active inhibitor of cholesterol absorption. J Med Chem. 1998;41(6):973–980.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–494. Top of Form.
   PubMed Web of Science ®Google Scholar
• Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47(1):1–9. .
   PubMed Web of Science ®Google Scholar
• Bec G, Meyer B, Gerard MA, et al. Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action on non-nucleoside inhibitors. J Am Chem Soc. 2013;135:9743–9752.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity and implications for drug design. Med Res Rev. 2013;33(Suppl 1):E1–72.
   PubMed Web of Science ®Google Scholar
• Namasivayam V, Vanangamudi M, Kramer MG, et al. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J Med Chem. 2019;62:4851–4883.
   PubMed Web of Science ®Google Scholar
• Beyrer C, Pozniak A. HIV drug resistance – an emerging threat to epidemic control. N Engl J Med. 2017;377:1605–1607.
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Gunthard HF, et al. 2017 update of the drug resistance mutations in HIV-1. Top HIV Med. 2017;24:132–133.
   Google Scholar
• Zhan P, Pannecouque C, De Clercq E, et al. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem. 2016;59:2849–2878.
   PubMed Web of Science ®Google Scholar
• Kang D, Fang Z, Li Z, et al. Design, synthesis and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J Med Chem. 2016;59:7991–8007.
   PubMed Web of Science ®Google Scholar
• Kang D, Fang Z, Huang B, et al. Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants. J Med Chem. 2017;60:4424–4443.
   PubMed Web of Science ®Google Scholar
• Kang D, Zhang H, Wang Z, et al. Identification of dihydrofuro[3,4-d]pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties. J Med Chem. 2019;62:1484–1501.
   PubMed Web of Science ®Google Scholar
• Kang D, Zhao T, Wang Z, et al. Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Commun Chem. 2019 Jun 28;2:74.
   Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463–469.
   PubMed Web of Science ®Google Scholar
• Shamovsky I, Connolly S, David L, et al. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline liophilicity relationships. J Med Chem. 2008;51:1162–1178.
   PubMed Web of Science ®Google Scholar
• Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000;97:12329–12333.
   PubMed Web of Science ®Google Scholar
• Carvalho JF, Louvel J, Doornbos ML, et al. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. J Med Chem. 2013;56:2828–2840.
   PubMed Web of Science ®Google Scholar
• Kang D, Arnold E, Liu X, et al. Discovery and characterization of fluorine-substituted diarypyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel. J Med Chem. 2020 Jan 14;63:1298–1312.
   PubMed Web of Science ®Google Scholar
• Jiang X, Yu J, Zhou Z, et al. Molecular design opportunities presented by solvent-exposed regions of target proteins. Med Res Rev. 2019;39:2194–2238.
   PubMed Web of Science ®Google Scholar
• Das K, Bauman JD, Clark AD, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci UDA. 2008;105:1466–1471.
   PubMed Web of Science ®Google Scholar
• Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014;66:638–675.
   PubMed Web of Science ®Google Scholar
• Gunosewoyo H, Coster M, Kassiou M. Molecular probes for the P2X7 receptor studies. Curr Med Chem. 2007;14:1505–1523.
   PubMed Web of Science ®Google Scholar
• Park J-H, Kim Y-C. P2X7 receptor antagonists: a patent review (2010-2015). Expert Opin Ther Pat. 2017;25:257–267.
   Google Scholar
• Furber M, Alcaraz L, Bent JE, et al. Discovery of potent and selective adamantane-based small-molecule P2X7 receptor antagonists/interleukin-1β inhibitors. J Med Chem. 2007;50:5882–5885.
   PubMed Web of Science ®Google Scholar
• Wilkinson SM, Gunosewoyo H, Barron ML, et al. The first CNS-active carborane: a novel P2X7 receptor antagonist with antidepressant activity. ACS Chem Neurosci. 2014;5:335–339.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630–1635.
   PubMed Web of Science ®Google Scholar
• Baxter A, Bent J, Bowers K, et al. Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003;13:4047–4050.
   PubMed Web of Science ®Google Scholar
• Guile SD, Alcaraz L, Birkinshaw TN, et al. Antagonists of the P2X7 receptor. from lead identification to drug development. J Med Chem. 2009;52:3123–3141.
   PubMed Web of Science ®Google Scholar
• Barniol-Xicota M, Kwak S-H, Lee S-D, et al. Escape from adamantane: scaffold optimization of novel P2X7 antagonists featuring complex polycycles. Bioorg Med Chem Lett. 2017;27:759–763.
   PubMed Web of Science ®Google Scholar
• Wilkinson SM, Barron ML, Kassoiu M, et al. Pharmacological evaluation of novel bioisosteres of an adamantyl benzamide P2X7 receptor antagonist. ACS Chem Neurosci. 2017 Aug 25;8:2374–2380.
   PubMed Web of Science ®Google Scholar
• Jasys VJ, Lombardo F, Appleton TA, et al. Preparation of fluoroadamantane acids and amines: impact of bridgehead fluorine substitution on the solution- and solid-state properties of functionalized adamantanes. J Am Chem Soc. 2000;122:466–473.
   Web of Science ®Google Scholar
• Zafrani Y, Saphier S, Gershonov E. Utilizing the CF2H moiety as a H-bond-donating group in drug discovery. Future Med Chem. 2020 Feb 6;12(5):361–365.
   PubMed Web of Science ®Google Scholar
• Levi N, Amir D, Gershonov E, et al. Recent progress on the Synthesis of CF2H-containing derivatives. Synthesis. 2019 Sept 30;51:4549–4567.
   Web of Science ®Google Scholar
• Huchet QA, Kuhn B, Wagner B, et al. Fluorination patterning: a study of structural motifs that impact physicochemical properties of relevance to drug discovery. J Med Chem. 2015 Nov 2;58:9041–9060.
   PubMed Web of Science ®Google Scholar
• Huchet QA, Trapp N, Kuhn B, et al. Partially fluorinated alkoxy groups – conformational adaptors to changing environments. J Fluorine Chem. 2017 Feb 8;198:34–46.
   Web of Science ®Google Scholar
• Erickson JA, McLoughlin JI. Hydrogen bond donor properties of the difluoromethyl group. J Org Chem. 1995;60(6):1626–1631.
   Web of Science ®Google Scholar
• Sessler CD, Rahm M, Becker S, et al. CF2H, a hydrogen bond donor. J Am Chem Soc. 2017 Jun 2;139(27):9325–9332.
   PubMed Web of Science ®Google Scholar
• Zafrani Y, Yeffet D, Sod-Moriah G, et al. Difluoromethyl bioisostere: examining the “lipophilic hydrogen bond donor” concept. J Med Chem. 2017 Jan 4;60:797–804.
   PubMed Web of Science ®Google Scholar
• Abraham MH, Abraham RJ, Byrne J, et al. NMR method for the determination of solute hydrogen bond acidity. J Org Chem. 2006;71:3389–3394.
   PubMed Web of Science ®Google Scholar
• Abraham MH, Abraham RJ, Acree WE, et al. An NMR method for the quantitative assessment of intramolecular hydrogen bonding; application to physicochemical, environmental and biochemical properties. J Org Chem. 2014;79:11075–11083.
   PubMed Web of Science ®Google Scholar
• Zafrani Y, Sod-Moriah G, Yeffet D, et al. CF2H, a functional group-dependent hydrogen-bond donor: is it a more or less lipophilic bioisostere of OH, SH and CH3? J Med Chem. 2019 May 15;62:5628–5637.
   PubMed Web of Science ®Google Scholar
• Butcher RA, Fujita M, Schroeder FC, et al. Small-molecule pheromones that control dauer development in Caenorhabditis elegans. Nat Chem Biol. 2007;3:420–422.
   PubMed Web of Science ®Google Scholar
• Patton JB, Bonne-Année S, Deckman J, et al. Methylprednisolone acetate induces, and ∆7-dafachronic acid suppresses, Strongyloides stercoralis hyperinfection in NSG mice. Proc Natl Acad Sci USA. 2018;115:204–209.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schaffer NE, Kliewer SA, et al. Nuclear receptors: emerging drug targets for parasitic diseases. J Clin Invest. 2017;127:1165–1171.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou XE, Motola DL, et al. Identification of the nuclear receptor DAF-12 as a therapeutic target in parasitic nematodes. Proc Natl Acad Sci USA. 2009;106:9138–9143.
   PubMed Web of Science ®Google Scholar
• Motola DL, Cummins CL, Rottiers V, et al. Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. Cell. 2006;124:1209–1223.
   PubMed Web of Science ®Google Scholar
• Dansey MV, Alvarez LD, Samaja G, et al. Synthetic DAF-12 modulators with potential use in controlling the nematode life cycle. Biochem J. 2015;465:175–184.
   PubMed Web of Science ®Google Scholar
• Rodriguez CR, Del Fueyo MC, Burton G, et al. Synthesis and biological activity of fluorinated analogues of the DAF-12 receptor antagonist 24-hydroxy-4-cholen-3-one. Steroids. 2019 Aug 7;151:108469.
   PubMed Web of Science ®Google Scholar
• Yang H, Rudge DG, Koos J, et al. mTOR kinase structure, mechanism and regulation. Nature. 2013;497:213–223.
   Web of Science ®Google Scholar
• Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signaling crosstalk. Nat Rev Mol Cell Biol. 2014;15:155–162.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism and disease. Cell. 2017;168:960–976.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Jacob S, Nair AB. A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus. Drugs Ther Perpect. 2017;33:290–301.
   Google Scholar
• Arachchige Don AS, Zheng XFS. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials. 2011;6:24–35.
   PubMedGoogle Scholar
• Shor B, Gibbons JJ, Abraham RT, et al. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8:3831–3837.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discovery. 2011;10:868–880.
   PubMed Web of Science ®Google Scholar
• Beaufils F, Cmiljanovic N, Cmiljanovic V, et al. 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridine-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as a clinical candidate in oncology. J Med Chem. 2017;60:7524–7538.
   PubMed Web of Science ®Google Scholar
• Rageot D, Bohnacker T, Malone A, et al. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridine-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. J Med Chem. 2018 Oct 25;61(22):10084–10105.
   PubMed Web of Science ®Google Scholar
• Brandt C, Hillmann P, Noack A, et al. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacol. 2018;140:107–120.
   PubMed Web of Science ®Google Scholar
• Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54:558–559.
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Int Med. 2005;258:94–114.
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255.
   PubMed Web of Science ®Google Scholar
• Goldsmith GA, Cordill S. The vasodilating effects of nicotinic acid (relation to metabolic rate and temperature). Am J Med Sci. 1943;205:204–208.
   Google Scholar
• Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992;93:102–104.
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effects of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1:195–202.
   PubMedGoogle Scholar
• Lorenzen A, Stannek C, Lang H, et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol. 2001;59:349–357.
   PubMed Web of Science ®Google Scholar
• Wise A, Ford SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278:9869–9874.
   PubMed Web of Science ®Google Scholar
• Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids demonstration of a metabolic type of sympathicolysis. Acta Med Scand. 2009;172(6):641–645.
   Google Scholar
• Carlson LA. Studies on the effects of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand. 1963;173:719–722.
   PubMed Web of Science ®Google Scholar
• Carlson LA, Hanngren A. Initial distribution in mice of 3H-labeled nicotinic acid studied with autoradiography. Life Sci. 1964;3:867–871.
   PubMed Web of Science ®Google Scholar
• Boatman PD, Richman JG, Semple G. Nicotinic acid receptor agonists. J Med Chem. 2008;51:7653–7662.
   PubMed Web of Science ®Google Scholar
• Imbriglio JE, Chang S, Liang R, et al. GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2009;19:2121–2124.
   PubMed Web of Science ®Google Scholar
• Boatman PD, Schrader TO, Kasem M, et al. Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a). Bioorg Med Chem Lett. 2010;20:2797–2800.
   PubMed Web of Science ®Google Scholar
• Imbriglio JE, Chang S, Liang R, et al. GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor G109a. Bioorg Med Chem Lett. 2010;20:4472.
   PubMed Web of Science ®Google Scholar
• Qin J, Rao A, Chen X, et al. Discovery of a potent nicotinic acid receptor agonist for the treatment of dyslipidemia. ACS Med Chem Lett. 2011 Feb 10;11(2):171–176.
   Google Scholar
• Hunter L. The C-F bond as a conformational tool in organic and biological chemistry. Beilstein J Org Chem. 2010;6:1–14. .
   PubMed Web of Science ®Google Scholar
• Zimmer LE, Sparr C, Gilmour R. Fluorine conformational effects in organocatalysis: an emerging strategy for molecular design. Angew Chem Int Ed. 2011;50:11860–11871.
   PubMed Web of Science ®Google Scholar
• Scheidt F, Selter P, Santschi N, et al. Emulating natural product conformation by cooperative, non-covalent fluorine interactions. Chem Eur J. 2017;23:6142–6149.
   PubMed Web of Science ®Google Scholar
• Thiehoff C, Rey YP, Gilmour R. The fluorine gauche effect: a brief history. Isr J Chem. 2017;57:92–100.
   Web of Science ®Google Scholar
• Aufiero M, Gilmour R. Informing molecular design by stereoelectronic theory: the fluorine gauche effect in catalysis. Acc Chem Res. 2018;51(7):1701–1710.
   PubMed Web of Science ®Google Scholar
• Thiehoff C, Holland MC, Daniliuc C, et al. Can acyclic conformational control be achieved via a sulfur-fluorine gauche effect? Chem Sci. 2015 Jun 1;6:3565–3571.
   PubMed Web of Science ®Google Scholar
• Thiehoff C, Schifferer L, Daniliuc CG, et al. The influence of electronic perturbations on the Sulfur–Fluorine Gauche Effect. J Fluorine Chem. 2016;186:121–126.
   Google Scholar
• Santschi N, Thiehoff C, Holland MC. The sulfur–fluorine gauche effect in coinage-metal complexes: augmenting conformational equilibria by complexation. Organometallics. 2016;35:3040–3044.
   Web of Science ®Google Scholar
• Huchet QA, Kuhn B, Wagner B, et al. On the polarity of partially fluorinated methyl groups. J Fluorine Chem. 2013 Mar 13;52:119–128.
   Google Scholar
• Müller K. Simple vector considerations to assess the polarity of partially fluorinated alkyl and alkoxy groups. Chimia (Aarau). 2014;68:356–362.
   PubMed Web of Science ®Google Scholar
• Molnár G, Thiehoff C, Holland MC, et al. Catalytic, Vicinal difluorination of olefins: creating a hybrid, chrial bioisostere of the trifluoromethyl and ethyl groups. ACS Catal. 2016;6:7167–7173.
   Web of Science ®Google Scholar
• Hara S, Nakahigashi J, Ishi-I K, et al. Difluorination of alkenes with iodotoluene difluoride. Synlett. 1998;1998:495–496.
   Google Scholar
• Molnár IG, Gilmour R. Catalytic difluorination of olefins. J Am Chem Soc. 2016 Mar 15;138:5004–5007.
   PubMed Web of Science ®Google Scholar
• Banik SM, Medley JW, Jacobsen EN. Catalytic, diastereoselective 1,2-difluorination of alkenes. J Am Chem Soc. 2016;138:5000–5003.
   PubMed Web of Science ®Google Scholar
• Sarie JC, Thiehoff C, Mudd RJ, et al. Deconstructing the catalytic, vicinal difluorination of alkenes: hf-free synthesis and structural study of p-TolIF2. J Org Chem. 2017;82:11792–11798.
   PubMed Web of Science ®Google Scholar
• Scheidt F, Schäfer M, Sarie JC, et al. Enantioslective, catalytic vicinal difluorination of alkenes. Angew Chem Int Ed. 2018;57:16431–16435.
   PubMed Web of Science ®Google Scholar
• Haj MK, Banik SM, Jacobsen EN. Catalytic, enantioselective 1,2-difluorination of cinnamamides. Org Lett. 2019 Apr 9;21:4919–4923.
   PubMed Web of Science ®Google Scholar
• Sharma S, Mathur AG, Pradhan S, et al. Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother. 2011;2:49–51.
   PubMedGoogle Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517.
   PubMed Web of Science ®Google Scholar
• Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature. Mult Scler Relat Disord. 2016;9:158–162.
   PubMed Web of Science ®Google Scholar
• Raffel J, Wakerley B, Nicholas R. Multiple sclerosis. Medicine (Baltimore). 2016 Jul 29;44:537–541.
   Google Scholar
• Brinkmann V, Billich A, Baumruker T. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discovery. 2010;9:883–897.
   PubMed Web of Science ®Google Scholar
• Mulakayala N, Rao P, Iqbal J, et al. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Eur J Med Chem. 2013;60:170–186.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee H, Lee M, et al. Efficient synthesis of the immunosuppressive agent FTY720. Synthesis. 2006;2006:753–755.
   Google Scholar
• Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod. 2011;74:900–907.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Fingolimod. CNS Drugs. 2011;25:673–698.
   PubMed Web of Science ®Google Scholar
• Erdeljac N, Kehr G, Ahlqvist M, et al. Exploring physicochemical space via a bioisostere of the trifluoroethyl and ethyl groups (BITE): attenuating liophilicity in fluorinated analogues of Gilenya® for multiple sclerosis. Chem Commun. 2018 Sept 7;54:12002–12005.
   PubMedGoogle Scholar
• Richon VM. Cancer Biology: mechanism of Antitumour Action of Vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006;95:S1–S6.
   PubMed Web of Science ®Google Scholar
• Mottamal M, Zheng S, Huang TL, et al. Deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–3941.
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu W-S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107:600–608.
   PubMed Web of Science ®Google Scholar
• Biel M, Wascholowski V, Giannis A. Epigenetics-An Epicenter of Gene Regulation: histones and Histone-Modifying Enzymes. Angew Chem Int Ed. 2005;44:3186–3216.
   PubMed Web of Science ®Google Scholar
• Holbert MA, Marmorstein R. Structure and activity of enzymes that remove histone modifications. Curr Opin Struct Biol. 2005;15:673–680.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637–656.
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discovery. 2006;5:37–50.
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonera B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6:579–589.
   PubMed Web of Science ®Google Scholar
• Walton JW, Cross JM, Reidel T, et al. Perfluorinated HDAC inhibitors as selective anticancer agents. Org Biomol Chem. 2017;15:9186–9190.
   PubMed Web of Science ®Google Scholar
• Erdeljac N, Bussmann K, Schöler A, et al. Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): validation of a Chiral Hybrid Bioisostere, BITE. ACS Med Chem Lett. 2019 Jul 19;10:1336–1340.
   PubMed Web of Science ®Google Scholar
• Kalin JH, Bergman JA. Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem. 2013;56:6297–6313.
   PubMed Web of Science ®Google Scholar
• Porter NJ, Osko JD, Diedrich D, et al. Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity. J Med Chem. 2018;61:8054–8060.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Krieger V, Groll M, et al. Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor. J Med Chem. 2018;61:10299–10309.
   PubMed Web of Science ®Google Scholar
• Marson CM, Matthews CJ, Atkinson SJ, et al. Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and N-92-aminophenyl)-benzamide binding unit. J Med Chem. 2015;58:6803–6818.
   PubMed Web of Science ®Google Scholar
• Mikami K, Itoh Y, Yamanaka M. Fluorinated carbonyl and olefinic compounds: basic character and asymmetric catalytic reactions. Chem Rev. 2004 Dec 19;104:1–16.
   PubMed Web of Science ®Google Scholar
• Ma J-A, Cahard D. Asymmetric fluorination, trifluoromethylation, and perfluoroalkylation reactions. Chem Rev. 2004 Oct 29;104:6119–6146.
   PubMed Web of Science ®Google Scholar
• Tur F, Saá JM. Direct, catalytic enantioselective nitroaldol (henry) reaction of trifluoromethyl ketones: an asymmetric entry to α-trifluoromethyl-substituted quaternary carbons. Org Lett. 2007 Nov 3;9:5079–5082.
   PubMed Web of Science ®Google Scholar
• Leroux F. Atropisomerism, biphenyls, and fluorine: a comparison of rotational barriers and twist angles. ChemBioChem. 2005;5:644–649.
   Web of Science ®Google Scholar
• Jagodzinska M, Huguenot F, Candiani G, et al. Assessing the bioisosterism of the trifluoromethyl group with a protease probe. ChemMedChem. 2009;4:49–51. .
   PubMed Web of Science ®Google Scholar
• Agrawal A, Romero-Perez D, Jacobsen JA, et al. Zinc-Binding groups modulate selective inhibition of MMPs. ChemMedChem. 2008;3:812–820.
   PubMed Web of Science ®Google Scholar
• Tochowicz A, Maskos K, Huber R, et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 sidechain to selectivity. J Mol Biol. 2007 Aug 24;371:989–1006.
   PubMed Web of Science ®Google Scholar
• Rowsell S, Hawtin P, Minshull CA, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol. 2002 May 24;319:171–181.
   Web of Science ®Google Scholar
• Brandstetter H, Grams F, Glitz D, et al. The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem. 2001 May 18;276:17405–17412.
   PubMed Web of Science ®Google Scholar
• Foley LH, Palermo R, Dunten P, et al. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11:969–972.
   PubMed Web of Science ®Google Scholar
• Dunten P, Kammlott U, Crowther R, et al. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin. Protein Sci. 2001 May 10;10:923–926.
   PubMed Web of Science ®Google Scholar
• Breyholz H-J, Schäfers M, Wagner S, et al. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J Med Chem. 2005 May 5;48(9):3400–3409.
   PubMed Web of Science ®Google Scholar
• Sheppeck JE, Gilmore JL, Tebben A, et al. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett. 2007 May 15;17:2769–2774.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101–1106.
   PubMed Web of Science ®Google Scholar
• Erdeljac N, Thiehoff C, Gilmour R, et al. Validating the 1,2-difluoro motif as a hybrid bioisostere of CF3 and Et using matrix metalloproteinases as structural probes. J Med Chem. 2020 May 7;63:6225–6237.
   PubMed Web of Science ®Google Scholar
• Venkatesan N, Kim BH. Synthesis and enzyme inhibitory activities of novel peptide isosteres. Curr Med Chem. 2002;9(24):2243–2270.
   PubMed Web of Science ®Google Scholar
• Gante J. Peptidomimetics—tailored enzyme inhibitors. Angew Chem Int Ed. 1994 Sept 16;33(17):1699–1720.
   Web of Science ®Google Scholar
• Wipf P, Henninger TC, Geib SJ. Methyl- and (trifluoromethyl)alkene peptide isosteres: synthesis and evaluation of their potential as β-turn promoters and peptide mimetics. J Org Chem. 1998;63:6088–6089.
   PubMed Web of Science ®Google Scholar
• Drouin M, Paquin J-F. Recent progress in the racemic and enantioselective synthesis of monofluoroalkene-based dipeptide isosteres. Beilstein J Org Chem. 2017;13:2637–2658.
   PubMed Web of Science ®Google Scholar
• Drouin M, Hamel J-F, Paquin J-F. Synthesis of monofluoroalkenes: a leap forward. Synthesis. 2018 Jan 11;50:881–955.
   Web of Science ®Google Scholar
• Courve-Bonnaire S, Cahard D, Pannecoucke X. Chiral dipeptide mimics possessing a fluoroolefin moiety: a relevant tool for conformational and medicinal studies. Org Biomol Chem. 2007;5:1151–1157.
   PubMed Web of Science ®Google Scholar
• Nadon J-F, Rochon K, Grastilleur S, et al. Synthesis of Gly-Ψ[(Z)CF=CH]-Phe, a fluoroalkene dipeptide isostere, and its incorporation into a Leu-enkephalin peptidomimetic. ACS Chem Neurosci. 2017;8:40–49.
   PubMed Web of Science ®Google Scholar
• Sani M, Volonterio A, Zanda M. The trifluoroethyl amine function as peptide bond replacement. ChemMedChem. 2007;2:1693–1700. .
   PubMed Web of Science ®Google Scholar
• Volonterio A, Bellosta S, Bravin F, et al. Synthesis, structure and conformation of partially-modified retro- and retro-inverse Ψ-[NHCH-(CF3)]Gly peptides. Chem Eur J. 2003;9:4150–4522.
   Web of Science ®Google Scholar
• Molteni M, Volonterioa A, Zanda M. Stereocontrolled Synthesis of ψ[CH(CF3)NH]Gly-Peptides. Org Lett. 2003 Sept 18;5:3887–3890.
   PubMed Web of Science ®Google Scholar
• Volonterio A, Bravo P, Zanda M. Synthesis of Partially Modified Retro and Retroinverso ψ[NHCH(CF3)]-Peptides. Org Lett. 2000 May 27;2:1827–1830.
   PubMed Web of Science ®Google Scholar
• Molteni M, Pesenti C, Sani M, et al. Fluorinated peptidomimetics; synthesis, conformational and biological features. J Fluorine Chem. 2004;125:1735–1743.
   Web of Science ®Google Scholar
• Molteni M, Bellucci MC, Bigotti S, et al. Ψ[CH(CF3)NH]Gly-peptides: synthesis and conformation analysis. Org Biomol Chem. 2009;7:2286–2296.
   PubMed Web of Science ®Google Scholar
• Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discovery Dev. 2005;8:619–630.
   PubMedGoogle Scholar
• Marquis RW. Inhibition of the Cysteine Protease Cathepsin K (EC 3.4.22.38). Ann Rep Med Chem. 2004;39:79–98.
   Web of Science ®Google Scholar
• Palmer JT, Bryant C, Wang D-X, et al. Design and Synthesis of Tri-Ring P3 Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K. J Med Chem. 2005 Oct 29;48(24):7520–7534.
   PubMed Web of Science ®Google Scholar
• Black WC, Bayly CI, Davis DE, et al. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Sept 9;15:4741–4744.
   PubMed Web of Science ®Google Scholar
• Isabel E, Mellon C, Boyd MJ, et al. Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. Bioorg Med Chem Lett. 2011;21:920–923.
   PubMed Web of Science ®Google Scholar
• Falgueyret J-P, Desmarais S, Oballa R, et al. Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies against Off-Target Cathepsins and Reduced Functional Selectivity. J Med Chem. 2005 Oct 29;48(24):7535–7543.
   PubMed Web of Science ®Google Scholar
• Li CS, Deschenes D, Desmarais S, et al. Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg Med Chem Lett. 2006;16:1985–1989.
   PubMed Web of Science ®Google Scholar
• Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Jan 15;18(3):923–928. .
   PubMed Web of Science ®Google Scholar
• Mullard A. Merck & Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discovery. 2016;15:669.
   Web of Science ®Google Scholar
• Halperin SD, Kwon D, Holmes M, et al. Development of a direct photocatalytic C-H fluorination for the preparative synthesis of odanacatib. Org Lett. 2015 Oct 20;17:5200–5203.
   PubMed Web of Science ®Google Scholar